Depakote Side Effects: Weight, Tremor, Liver, and Monitoring

Depakote can calm manic episodes, but the side effect list on the pharmacy printout can feel alarming, with liver warnings, blood tests, and a pregnancy warning in capital letters. Most people deal with far more ordinary issues, like nausea, drowsiness, or a shaky hand. You deserve to know which effects are common, which are rare but serious, and exactly what monitoring should look like.

Depakote works on your brain’s signaling, and like any medicine that circulates through your whole body, it also reaches your liver, blood, and metabolism. The label notes its antiseizure effect may involve higher brain levels of GABA, a calming chemical messenger, though the mechanism in mania isn’t established. Because nearly all of it is processed by the liver, safe use depends on precision in tracking liver health, blood counts, and drug levels over time.

The standard reference is the FDA label. Depakote’s prescribing information, revised in March 2026, lists side effects from controlled trials, carries a boxed warning, and spells out which lab tests to run. In two 3-week trials for acute mania, Depakote beat placebo on every outcome measure. The results are real, and the science is well established.

But a label written for every indication isn’t a personal monitoring plan, and at Siggy we believe you should understand your own lab schedule and warning signs before you need them. This guide turns the label into plain language: what’s common, what’s rare, which tests to expect and when, and what the pregnancy warning means in numbers. Knowing the difference is what turns worry into clinical decisions grounded in evidence.

What This Page Covers

• The Short Answer
• Common Side Effects in the First Weeks
• Weight Gain, Tremor, and Hair Loss
• Liver, Pancreas, and Blood Warnings
• Your Lab Monitoring Schedule
• The Pregnancy Warning, Clearly
• When to Call Right Away

The Short Answer

Depakote (divalproex sodium) is FDA approved for manic episodes of bipolar disorder, certain seizures, and migraine prevention. Its most common side effects are stomach upset, sleepiness, dizziness, tremor, hair loss, and weight gain. Its rare but serious risks include liver injury, pancreatitis, low platelets, and high ammonia, which is why lab monitoring matters.

The biggest safety issue for many people is pregnancy. Valproate can cause major birth defects and lower IQ in exposed children, so anyone who could become pregnant needs a clear conversation with their prescriber first.

Common Side Effects in the First Weeks

The label’s data for bipolar disorder come from two 3-week, placebo-controlled trials in people hospitalized for acute mania:

Side Effect	Depakote	Placebo
Nausea	22%	15%
Sleepiness	19%	12%
Dizziness	12%	4%
Vomiting	12%	3%
Accidental injury	11%	5%
Weakness	10%	7%

Vomiting was the only side effect significantly more common than with placebo in those trials. About 8% of people on Depakote stopped because of side effects, compared with 4% on placebo and 11% on lithium.

For stomach upset, the label suggests taking Depakote with food or building up the dose slowly from a low start. Depakote tablets should be swallowed whole, never crushed or chewed. It can also cause drowsiness, so avoid driving until you know how it affects you, and avoid alcohol, which the Medication Guide warns can worsen sleepiness and dizziness.

Weight Gain, Tremor, and Hair Loss

These side effects often show up later and tend to be dose-related.

• Tremor: In the label’s epilepsy monotherapy trial, 57% of people on high doses had tremor, compared with 19% on low doses.
• Hair loss: Hair loss affected 24% on high doses versus 13% on low doses, and the label’s postmarketing reports include changes in hair texture and color.
• Weight gain: In the migraine trials, 8% gained weight on Depakote versus 2% on placebo. A 2025 meta-analysis of antiseizure medicines found adults on long-term valproate had a BMI about 2.7 points higher than healthy controls.

A Cochrane review of valproate for mania found valproate caused less weight gain and sedation than olanzapine, a common alternative. If weight, tremor, or hair changes bother you, raise them early, since the dose can often be adjusted.

For women, there’s one more metabolic effect to know. In a study of 230 women with bipolar disorder, irregular periods with signs of high androgens, such as acne or excess hair growth, developed in 10.5% of those on valproate, compared with 1.4% on other mood stabilizers, always within the first year.

Liver, Pancreas, and Blood Warnings

Depakote’s boxed warning covers three serious risks. They’re rare, but knowing the early signs matters.

• Liver injury: Liver failure, sometimes fatal, has occurred, usually in the first 6 months. Early signs include weakness, feeling unwell, facial swelling, loss of appetite, and vomiting. Risk is highest in children under 2 and people with certain mitochondrial disorders, and the label notes fatal liver injury becomes considerably less common in older age groups.
• Pancreatitis: Life-threatening pancreatitis has been reported, both soon after starting and after years of use. In clinical trials, there were 2 cases without another cause among 2,416 patients. Severe stomach pain that may spread to the back, nausea, and vomiting need prompt evaluation.
• Fetal harm: This is covered in detail below.

Beyond the boxed warning, low platelets are dose-related. In one epilepsy trial at about 50 mg/kg a day, 27% of patients had at least one low platelet reading, and risk rose at total valproate levels of 110 mcg/mL or higher in women and 135 mcg/mL or higher in men. High ammonia can also occur, even with normal liver tests, and may cause confusion, lethargy, or vomiting. The label adds a caution for older adults, who may need a lower starting dose because of sleepiness.

Your Lab Monitoring Schedule

The label doesn’t set exact dates, so your prescriber chooses the timing. This table summarizes what the label calls for, plus weight tracking supported by the metabolic research above:

When	What’s Checked	Why
Before starting	Liver tests, blood count with platelets, clotting tests	Establishes your baseline
First 6 months	Liver tests at frequent intervals	Serious liver injury usually occurs in this window
Early and after medication changes	Valproate blood level	Other drugs can raise or lower levels
Periodically	Blood count and clotting tests	Platelet drops are dose-related
Before surgery or during pregnancy	Blood count and clotting tests	Bleeding risk
If symptoms appear	Ammonia level	Checks for high ammonia
Ongoing	Weight	Long-term use can raise BMI

In the mania trials, people were dosed to response with trough levels between 50 and 125 mcg/mL. The label also warns that labs alone can miss early liver injury, so symptoms and check-ins matter as much as test results.

Some interactions change levels. Estrogen-containing birth control, carbapenem antibiotics, aspirin, and methotrexate can all affect valproate, and topiramate raises the risk of high ammonia. Tell every prescriber and pharmacist you take Depakote.

The Pregnancy Warning, Clearly

This warning is serious. According to the label, valproate shouldn’t be used in women who are pregnant, planning pregnancy, or able to become pregnant unless other medications have failed or are otherwise unacceptable. If it’s used, effective contraception is required. For migraine prevention, it’s contraindicated in pregnancy.

Here’s what the numbers mean:

• Major birth defects: The label reports major malformations in 9 to 11% of babies exposed to valproate, compared with a 2 to 4% background risk. In a North American registry analysis, the rate was 9.3% after first-trimester valproate, compared with 2.0% for lamotrigine.
• Spina bifida: The risk is about 1 to 2% after exposure, compared with 0.06 to 0.07% in the general population.
• IQ: In the NEAD study, children exposed to valproate had an average IQ of 97 at age 6, compared with 105 to 108 after exposure to three other antiseizure medicines, with lower scores at higher doses.
• Other outcomes: The label links exposure to a higher risk of autism and ADHD, though estimates vary across studies.

Folic acid before and during early pregnancy is recommended, but the label notes it’s not known whether it lowers valproate’s specific risks. Estrogen-containing birth control can also lower valproate levels, so your prescriber may recheck levels when you start or stop it.

If you’re taking Depakote and think you might be pregnant, call your prescriber right away. An FDA safety communication advises against stopping valproate suddenly on your own, because that can cause serious problems for you or the pregnancy. The label also lists reports of male infertility, so men planning to father a child should raise it too.

When to Call Right Away

Call 911 if you have trouble breathing, swelling of the face, lips, or throat, a seizure, or you can’t stay awake. Call or text 988 if you have thoughts of suicide, since antiseizure medicines, including Depakote, carry a warning about suicidal thoughts.

Call your prescriber right away for:

• Yellow skin or eyes, dark urine, right-sided abdominal pain, or vomiting that won’t stop
• Severe stomach pain, especially if it spreads to your back
• Unusual bruising, bleeding, or tiny red or purple spots on your skin
• New confusion, extreme tiredness, or vomiting, which may signal high ammonia
• Fever with rash or swollen glands
• A possible pregnancy

With a medication like Depakote, checking in is part of using it safely.

Depakote’s side effects are manageable for many people when they’re tracked: common ones ease with food and dose changes, and rare serious ones are caught through labs and early warning signs. For how Depakote works and how it compares with lithium, see our guide to Depakote for bipolar disorder.

Ready to take control of your mental health? Start your anonymous intake with Siggy and get your plan reviewed by a licensed prescriber.

This article is for education only and isn’t a substitute for personal medical advice. Don’t change or stop a medication without talking to your prescriber. It was reviewed for clinical accuracy and reflects sources available as of September 2026.